Immunoprecise Antibodies Ltd Stock Other OTC
Stocks
CA87588T1030
Pharmaceuticals
| Market Cap | 89.06M 63.9M 55.32M 51.71M 47.26M 6.09B 90.45M 606M 238M 3.05B 240M 235M 10.15B | P/E 2027 * |
-6.12x | P/E 2028 * | -8x |
|---|---|---|---|---|---|
| Enterprise Value | 89.06M 63.9M 55.32M 51.71M 47.26M 6.09B 90.45M 606M 238M 3.05B 240M 235M 10.15B | EV / Sales 2027 * |
4.4x | EV / Sales 2028 * | 3.58x |
| Free-Float |
90.86% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript: Immunoprecise Antibodies Ltd
| 1 day | -6.29% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 2018-02-20 |
Richard Areglado
DFI | Director of Finance/CFO | 62 | 2025-10-19 |
Hyfte Van
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
BRD | Director/Board Member | - | 2018-05-23 |
Dirk Witters
CHM | Chairman | - | - |
Jonathan Lieber
BRD | Director/Board Member | 56 | 2025-07-06 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.29% | -23.22% | - | - | 63.9M | |
| +3.02% | +6.43% | +43.53% | +1.90% | 80.69B | |
| +0.84% | +10.26% | -0.15% | +27.24% | 51.22B | |
| +0.90% | +1.67% | +22.01% | +176.54% | 49.58B | |
| +2.99% | +8.18% | -48.46% | -49.18% | 45.5B | |
| -0.39% | +2.63% | +58.51% | -23.02% | 30.6B | |
| +0.82% | +2.63% | +55.06% | +85.54% | 24.64B | |
| +1.08% | +8.47% | +128.98% | -40.36% | 23.88B | |
| 0.00% | +13.14% | +6.63% | +202.17% | 21.59B | |
| -0.62% | +3.30% | +65.10% | +114.68% | 16.48B | |
| Average | +0.37% | +4.26% | +36.80% | +55.06% | 38.24B | |
| Weighted average by Cap. | +1.42% | +4.36% | +28.57% | +42.88% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 20.24M 14.53M 12.58M 11.75M 10.74M 1.39B 20.56M 138M 54.09M 693M 54.55M 53.36M 2.31B | 24.9M 17.87M 15.47M 14.46M 13.21M 1.7B 25.29M 170M 66.52M 852M 67.08M 65.62M 2.84B |
| Net income | -14.81M -10.63M -9.2M -8.6M -7.86M -1.01B -15.04M -101M -39.57M -507M -39.91M -39.04M -1.69B | -11.81M -8.47M -7.33M -6.85M -6.26M -808M -11.99M -80.38M -31.54M -404M -31.81M -31.11M -1.35B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
